GlassScriptPhysician profile
Frantz Saint Fleur
NPI 1194506717
$3,802.38
in general payments reported to CMS, 2019-2025
22 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,372 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,463 · Travel and Lodging: $1,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,463.14 |
| Travel and Lodging | $1,339.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,301.23 | 2024-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $189.08 | 2025 | Farxiga, Airsupra, Breztri |
| Neurocrine Biosciences, INC. | $186.25 | 2025 | |
| Pfizer INC. | $146.81 | 2025 | |
| Cequr Corporation | $144.30 | 2025 | Cequr Simplicity |
| Lilly USA, LLC | $140.05 | 2025 | Jardiance, Zepbound, Mounjaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.89 | 2024 | Lifevest |
| Lundbeck LLC | $85.43 | 2025 | Rexulti |
| Exact Sciences Corporation | $75.57 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $56.79 | 2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $49.17 | 2025 | Rexulti |
| Abbvie INC. | $44.42 | 2025 | |
| Amneal Pharmaceuticals LLC | $42.44 | 2025 | Unithroid |
| Kowa Pharmaceuticals America, INC. | $34.51 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.28 | 2025 | Jascayd |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $30.78 | 2025 | |
| Novartis Pharmaceuticals Corporation | $29.25 | 2025 | |
| Verona Pharma, INC. | $25.58 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $24.29 | 2025 | Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.14 | 2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $22.23 | 2025 | Gemtesa |
| Alnylam Pharmaceuticals INC. | $21.89 | 2025 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frantz Saint Fleur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.